Method Sign up free

Borrower record · Q2 2026

X4 Pharmaceuticals

As filed by Hercules Capital, Inc. · period end 30 June 2026No sector — one filer, nothing to corroborate

Hercules Capital, Inc. is the only BDC lending to X4 Pharmaceuticals: $77.2m across two positions at Q2 2026, marked at par.

Filed fair value
$77.2m
2 funded positions
Aggregate mark
99.6c
cost filed on all 2 positions
Filed spread
315bp
over Prime, one floating tranche
Maturities to
2027
one date, 1 July 2027
Periods on record
5
Q2 2025 → Q2 2026

How this total is counted

Capital structure

First-Lien Senior Secured1 position
$77.2m
>99.9%
Equity/Other1 position
$8k
<0.1%

All 2 funded positions carry a filed seniority.

Rate structure

Floating, on the one position whose interest type a filer disclosed.

1 of 2 funded positions carries no filed interest type.

Maturity profile

1 of 2 funded positions dated
2027
$77.2m

1.0 years to maturity, weighted by fair value across the 1 dated position.

Filed over time

5 periods · aggregate only

Filed fair value

$73.8m
Q2 2025
$76.7m
Q3 2025
$76.7m
Q4 2025
$76.7m
Q1 2026
$77.2m
Q2 2026

Aggregate marknot to zero

92.9c
Q2 2025
96.2c
Q3 2025
96.0c
Q4 2025
99.3c
Q1 2026
99.6c
Q2 2026

Q2 2025, Q3 2025, Q4 2025, Q1 2026, Q2 2026 — every filer reporting the borrower at each period, aggregated. No lender is separated out at any period.

Credit flags

The filer reports no position on non-accrual, and no filed tranche pays in kind.

Not in the filings

Sign up for free

Tell me when this changes.

One lender reports X4 Pharmaceuticals today. We will email you when a second one does, when Hercules Capital, Inc.'s mark moves, or when the position leaves the schedule.

Every filing behind this page

1 filer · Q2 2026
FilerCIKFormPeriodFiledAccession
Hercules Capital, Inc. (HTGC)000128078410-Q2026-06-302026-07-300001280784-26-000042

Related borrowers

Same lender